Compare Incyte Corporation (INCY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tesla, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 64.8× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Tesla, Inc. for 88 Days on average.
| INCY | TSLA | |
|---|---|---|
Market Cap | $22.85B | $1.48T |
Volume | 1,927,029 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $489.88 |
52-Week Low | $83.80 | $298.16 |
Typical Hold Time | 33 Days | 88 Days |
Enterprise Value | $18.35B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Tesla (TSLA) trades at $375.03, down 0.68% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue at $94.83B in 2025 and a net income margin of 4%. Analyst consensus is a Buy with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and high valuation multiples. The stock offers growth potential from AI and robotics expansion, but faces headwinds from competitive pressures and margin compression. Investors should weigh long-term disruptive potential against current profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
